Roth Capital Cuts PT on Heat Biologics (HTBX) by ~27% Following HS-410 Phase 2 Data

December 1, 2016 8:25 AM EST Send to a Friend
Roth Capital cuts its price target on Buy-rated Heat Biologics (Nasdaq: HTBX) from $2.75 to $2 following adverse HS-410 combo ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login